Modality
Bispecific Ab
MOA
PCSK9i
Target
BET
Pathway
RNA Splicing
AsthmaPTSD
Development Pipeline
Preclinical
~May 2018
→ ~Aug 2019
Phase 1
Nov 2019
→ Mar 2026
Phase 1Current
NCT03949276
134 pts·Asthma
2019-11→TBD·Completed
NCT04326617
1,159 pts·Asthma
2024-12→2026-03·Terminated
1,293 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-12-283mo agoOrphan Drug· PTSD
2026-03-093w agoPh2 Data· Asthma
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P1/2
Complet…
P1/2
Termina…
Catalysts
Orphan Drug
2025-12-28 · 3mo ago
PTSD
Ph2 Data
2026-03-09 · 3w ago
Asthma
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03949276 | Phase 1/2 | Asthma | Completed | 134 | Biomarker |
| NCT04326617 | Phase 1/2 | Asthma | Terminated | 1159 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET |